These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 1808338)

  • 61. Mechanisms of improved physical performance of chronic hemodialysis patients after erythropoietin treatment.
    Grunze M; Kohlmann M; Mulligan M; Grüner I; Koeppel M; Bommer J
    Am J Nephrol; 1990; 10 Suppl 2():15-8; discussion 18-23. PubMed ID: 2124412
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Analysis of the factors in the cases resistant to recombinant human erythropoietin treatment.
    Suzuki M
    Contrib Nephrol; 1990; 82():65-71. PubMed ID: 2093529
    [No Abstract]   [Full Text] [Related]  

  • 63. Reticulocyte count used to assess recombinant human erythropoietin sensitivity in hemodialysis patients.
    Tatsumi N; Kojima K; Tsuda I; Yamagami S; Itoh Y; Tanaka H
    Contrib Nephrol; 1990; 82():41-8. PubMed ID: 2093525
    [No Abstract]   [Full Text] [Related]  

  • 64. Effects of recombinant human erythropoietin on cerebral and cutaneous blood flow and on blood coagulability.
    Johnson WJ; McCarthy JT; Yanagihara T; Osmundson PJ; Ilstrup DM; Jenson BM; Bowie EJ
    Kidney Int; 1990 Nov; 38(5):919-24. PubMed ID: 2266676
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical experience with recombinant human erythropoietin in hemodialysis patients.
    Schaefer RM; Kuerner B; Zech M; Heidland A
    Pol Arch Med Wewn; 1988 Oct; 80(4):213-20. PubMed ID: 3078210
    [No Abstract]   [Full Text] [Related]  

  • 66. Hemodynamics in hemodialysis patients treated with recombinant human erythropoietin.
    Nonnast-Daniel B; Schäffer J; Frei U
    Contrib Nephrol; 1989; 76():283-9; discussion 290-1. PubMed ID: 2684528
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Lymphocyte subsets and delayed cutaneous hypersensitivity in hemodialysis patients receiving recombinant human erythropoietin.
    Pfåffl W; Gross HJ; Neumeier D; Nattermann U; Samtleben W; Gurland HJ
    Contrib Nephrol; 1988; 66():195-204. PubMed ID: 3391032
    [No Abstract]   [Full Text] [Related]  

  • 68. Erythropoietin treatment does not compromise cardiovascular function in chronic renal failure.
    Haedersdal C; Mehlsen J; Stenver D; Nielsen B; Jeppesen L; Winther K
    Angiology; 1994 Mar; 45(3):231-4. PubMed ID: 8129205
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evaluation of platelet hyperfunction in hemodialysis patients receiving recombinant human erythropoietin.
    Zirkman DM; Zeigler ZR; Fraley DS; Bruns FJ; Adler S
    Am J Kidney Dis; 1993 Jan; 21(1):31-7. PubMed ID: 8418623
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Recombinant human erythropoietin increases platelet aggregation in chronic hemodialysis patients.
    Sayinalp N; Erdem Y; Ilhami Ozcebe O; Büyükaşik Y; Cağlar S; Dündar SV
    Thromb Res; 1998 May; 90(4):195-8. PubMed ID: 9692619
    [No Abstract]   [Full Text] [Related]  

  • 71. Side effects during recombinant human erythropoietin therapy in 2,000 ESRD patients.
    Samtleben W; Ehmer B; Lutz-Knochenhauer I; Hagmann C; Scigalla P; Gurland HJ
    Contrib Nephrol; 1991; 88():107-16; discussion 117. PubMed ID: 2040172
    [No Abstract]   [Full Text] [Related]  

  • 72. Effects of human recombinant erythropoietin on anaemia, systemic haemodynamics and renal function in predialysis renal failure patients.
    Onoyama K; Kumagai H; Takeda K; Shimamatsu K; Fujishima M
    Nephrol Dial Transplant; 1989; 4(11):966-70. PubMed ID: 2516888
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Urea kinetics in patients on regular dialysis treatment before and after treatment with recombinant human erythropoietin.
    Zehnter E; Pollok M; Ziegenhagen D; Bramsiepe P; Longere F; Baldamus CA; Wellner U; Waters W
    Contrib Nephrol; 1988; 66():149-55. PubMed ID: 3391029
    [No Abstract]   [Full Text] [Related]  

  • 74. Erythropoietin 1997: a brief update.
    Gahl GM; Eckardt KU
    Perit Dial Int; 1997; 17 Suppl 2():S84-90. PubMed ID: 9163805
    [No Abstract]   [Full Text] [Related]  

  • 75. Relation between blood pressure and hematocrit in anephric patients treated by means of recombinant DNA human erythropoietin.
    Iorio L; Saltarelli G; Nacca RG; Violi F
    Nephron; 1996; 72(2):373-4. PubMed ID: 8684581
    [No Abstract]   [Full Text] [Related]  

  • 76. Thrombocytosis in EPO-treated dialysis patients may be mediated by EPO rather than iron deficiency.
    Vaziri ND
    Am J Kidney Dis; 2009 May; 53(5):733-6. PubMed ID: 19303685
    [No Abstract]   [Full Text] [Related]  

  • 77. Does treatment of predialysis patients with recombinant human erythropoietin compromise renal function?
    Koene RA; Frenken LA
    Contrib Nephrol; 1990; 87():105-12. PubMed ID: 2093536
    [No Abstract]   [Full Text] [Related]  

  • 78. [Variability of the response to recombinant human erythropoietin in patients undergoing hemodialysis treatment].
    Baroni A; Airoldi G; Agliata S; Fortina F; Ragazzoni E; Cavagnino A; De Nigris A; Cametti G; Ferrero D; Fortina A
    Minerva Urol Nefrol; 1991; 43(3):131-5. PubMed ID: 1817334
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Hemo-rheologic changes following treatment with human recombinant erythropoietin in chronic hemodialysis patients].
    Melappioni M; Giansanti R; Boemi M; Baldassari M; Baldini S; Pierangeli T; Radicioni R; Fumelli P; Panichi N
    Minerva Urol Nefrol; 1992; 44(2):155-9. PubMed ID: 1411865
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Erythropoietin and hypertension].
    Frei U; Nonnast-Daniel B; Koch KM
    Klin Wochenschr; 1988 Sep; 66(18):914-9. PubMed ID: 3054276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.